XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and License Agreement - Additional Information (Details) - Bristol-Myers Squibb Company - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2020
May 31, 2020
Mar. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Non-refundable upfront payment received     $ 50,000,000  
Collaboration and License Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Collaboration term expiration period   42 months    
Initial nonrefundable upfront fee received $ 50,000,000      
Non-refundable upfront payment received   $ 50,000,000    
Deferred revenue recognized     200,000  
Deferred revenue     49,700,000 $ 49,900,000
Deferred revenue, current     2,100,000 2,100,000
Deferred revenue, noncurrent     $ 47,600,000 $ 47,800,000
Collaboration and License Agreement | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Milestone payments entitled to be received   301,000,000    
Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Milestone payments entitled to be received   176,000,000    
Collaboration and License Agreement | Maximum | Commercial Milestones        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Milestone payments entitled to be received   $ 125,000,000